Amplexd Therapeutics has secured $2 million in funding from an Asia-based family office specializing in life sciences. This investment supports the finalization of product development and the initiation of Phase 1/2 clinical trials for non-invasive treatments targeting Cervical Intraepithelial Neoplasia (CIN). “The funding marks a major milestone in our R&D efforts for our two therapies after extremely promising preclinical studies were completed.…
![](https://femtechinsider.com/wp-content/uploads/2024/05/alia-rahman-amplexd-1170x658.png)